{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:53:56Z","timestamp":1791233636547,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blinatumomab (BLINA) causes immune-related toxicities, such as cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome (ICANS). Although hyponatremia associated with interleukin (IL)-6\u2013mediated vasopressin secretion has been reported with chimeric antigen receptor T-cell therapy, similar reports with bispecific antibodies are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A woman in her 60s with B-cell acute lymphoblastic leukemia developed grade 3 ICANS on day 3 of the second BLINA cycle. On day 13, the patient experienced grade 4 hyponatremia (serum sodium, 106 mmol\/L). Treatment with 3% saline and tolvaptan improved symptoms. No other causes, such as central nervous system disease, adrenal insufficiency, or thyroid dysfunction, were identified. Based on the clinical findings and the exclusion of other etiologies, BLINA-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) was diagnosed. After confirming a decrease in IL-6 levels, tolvaptan was tapered and discontinued, and no recurrence of hyponatremia was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BLINA may be involved in SIADH development, potentially via increased central IL-6 levels following ICANS treatment, which may promote arginine vasopressin secretion. In patients who develop ICANS during BLINA therapy, close monitoring of serum sodium levels may be a useful part of neurological assessment. If hyponatremia occurs, clinicians should promptly consider SIADH and initiate the appropriate management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00606-x","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:57:42Z","timestamp":1783677462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Syndrome of inappropriate antidiuretic hormone secretion following immune effector cell\u2013associated neurotoxicity syndrome during blinatumomab therapy: a case report"],"prefix":"10.1186","volume":"12","author":[{"given":"Misato","family":"Yoshihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Yasumuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohkan","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"606_CR1","doi-asserted-by":"publisher","first-page":"e200111","DOI":"10.1212\/NXI.0000000000200111","volume":"10","author":"S Huby","year":"2023","unstructured":"Huby S, Gelisse P, Tudesq JJ, Labauge P, Duflos C, Cartron G, et al. Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200111. https:\/\/doi.org\/10.1212\/NXI.0000000000200111.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"606_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5414\/CN109872","volume":"93","author":"BN Dixon","year":"2020","unstructured":"Dixon BN, Daley RJ, Buie LW, Hsu M, Park JH, Brentjens RJ, et al. Correlation of IL-6 secretion and hyponatremia with the use of CD19\u2009+\u2009chimeric antigen receptor T-cells. Clin Nephrol. 2020;93:42\u20136. https:\/\/doi.org\/10.5414\/CN109872.","journal-title":"Clin Nephrol"},{"key":"606_CR3","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1210\/jcem.79.4.7962300","volume":"79","author":"G Mastorakos","year":"1994","unstructured":"Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab. 1994;79:934\u20139. https:\/\/doi.org\/10.1210\/jcem.79.4.7962300.","journal-title":"J Clin Endocrinol Metab"},{"key":"606_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1507\/endocrine.99.S.July_1","volume":"99","author":"Japan Endocrine Society","year":"2023","unstructured":"Japan Endocrine Society. Kann\u014d Kasuitai Kin\u014d Sh\u014dgai to Sentensei Jinsei Ny\u014dh\u014dsh\u014d oyobi Kanren Shikkan no Shinry\u014d Gaidorain 2023-nenban [Guideline 2023 for hypothalamic pituitary dysfunction, congenital nephrogenic diabetes insipidus and related diseases]. Folia Endocrinol Jpn. 2023;99:1\u2013171. https:\/\/doi.org\/10.1507\/endocrine.99.S.July_1.","journal-title":"Folia Endocrinol Jpn"},{"key":"606_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1365-2265.2006.02583.x","volume":"65","author":"G Gill","year":"2006","unstructured":"Gill G, Huda B, Boyd A, Skagen K, Wile D, Watson I, et al. Characteristics and mortality of severe hyponatraemia\u2014a hospital-based study. Clin Endocrinol. 2006;65:246\u20139. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02583.x.","journal-title":"Clin Endocrinol"},{"key":"606_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.ejim.2015.10.020","volume":"26","author":"D Shepshelovich","year":"2015","unstructured":"Shepshelovich D, Leibovitch C, Klein A, Zoldan S, Milo G, Shochat T, et al. The syndrome of inappropriate antidiuretic hormone secretion: distribution and characterization according to etiologies. Eur J Intern Med. 2015;26:819\u201324. https:\/\/doi.org\/10.1016\/j.ejim.2015.10.020.","journal-title":"Eur J Intern Med"},{"key":"606_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1210\/endrev\/bnad010","volume":"44","author":"AM Warren","year":"2023","unstructured":"Warren AM, Grossmann M, Christ-Crain M, Russell N. Syndrome of inappropriate antidiuresis: from pathophysiology to management. Endocr Rev. 2023;44:819\u201361. https:\/\/doi.org\/10.1210\/endrev\/bnad010.","journal-title":"Endocr Rev"},{"key":"606_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF01788840","volume":"4","author":"T Berghmans","year":"1996","unstructured":"Berghmans T. Hyponatremia related to medical anticancer treatment. Support Care Cancer. 1996;4:341\u201350. https:\/\/doi.org\/10.1007\/BF01788840.","journal-title":"Support Care Cancer"},{"key":"606_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood.V45.3.315.315","volume":"45","author":"MJ Stuart","year":"1975","unstructured":"Stuart MJ, Cuaso C, Miller M, Oski FA. Syndrome of recurrent increased secretion of antidiuretic hormone following multiple doses of vincristine. Blood. 1975;45:315\u201320. https:\/\/doi.org\/10.1182\/blood.V45.3.315.315.","journal-title":"Blood"},{"key":"606_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib\u2013blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2016272.","journal-title":"N Engl J Med"},{"key":"606_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/j.1528-1167.2005.64004.x","volume":"46","author":"K Nasrallah","year":"2005","unstructured":"Nasrallah K, Silver B. Hyponatremia associated with repeated use of levetiracetam. Epilepsia. 2005;46:972\u20133. https:\/\/doi.org\/10.1111\/j.1528-1167.2005.64004.x.","journal-title":"Epilepsia"},{"key":"606_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13760-017-0825-4","volume":"118","author":"EC Rosca","year":"2018","unstructured":"Rosca EC, Simu M. Levetiracetam-induced hyponatremia. Acta Neurol Belg. 2018;118:123\u201324. https:\/\/doi.org\/10.1007\/s13760-017-0825-4.","journal-title":"Acta Neurol Belg"},{"key":"606_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1177\/1078155215592023","volume":"22","author":"J Hill","year":"2016","unstructured":"Hill J, Shields J, Passero V. Tyrosine kinase inhibitor-associated syndrome of inappropriate secretion of anti-diuretic hormone. J Oncol Pharm Pract. 2016;22:729\u201332. https:\/\/doi.org\/10.1177\/1078155215592023.","journal-title":"J Oncol Pharm Pract"},{"key":"606_CR14","doi-asserted-by":"publisher","first-page":"e23080","DOI":"10.7759\/cureus.23080","volume":"14","author":"S Peer","year":"2022","unstructured":"Peer S, Sharma DA, Prasad C, Kulanthaivelu K. Acute severe hypovolemic hyponatremia in a patient on intravenous dexamethasone. Cureus. 2022;14:e23080. https:\/\/doi.org\/10.7759\/cureus.23080.","journal-title":"Cureus"},{"key":"606_CR15","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226\u201333. https:\/\/doi.org\/10.1182\/blood-2012-01-400515.","journal-title":"Blood"},{"key":"606_CR16","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404\u201319. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698.","journal-title":"Cancer Discov"},{"key":"606_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"606_CR18","doi-asserted-by":"publisher","first-page":"1739021","DOI":"10.3389\/fneur.2026.1739021","volume":"17","author":"F Aziz","year":"2026","unstructured":"Aziz F, Chakraborty A, Saha D, Dutta P. Immune effector cell-associated neurotoxicity syndrome: integrative mechanisms, predictive biomarkers, and translational pathways for prevention in CAR T-cell therapy. Front Neurol. 2026;17:1739021. https:\/\/doi.org\/10.3389\/fneur.2026.1739021.","journal-title":"Front Neurol"},{"key":"606_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00277-018-3497-0","volume":"98","author":"AS Stein","year":"2019","unstructured":"Stein AS, Schiller G, Benjamin R, Jia C, Zhang A, Zhu M, et al. Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98:159\u201367. https:\/\/doi.org\/10.1007\/s00277-018-3497-0.","journal-title":"Ann Hematol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00606-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:02:56Z","timestamp":1791230576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00606-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00606-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9674917\/v1","asserted-by":"object"}]},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Research Ethics Committee of Kameda Medical Center (number: 24\u2013042). Informed consent was obtained from the patient for writing this report.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent for publication was obtained from the patient.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"84"}}